Loading organizations...
T1D Exchange is a non-profit improving care and outcomes for individuals with type 1 diabetes. It facilitates research across technology, medication, and patient management. The organization establishes a learning platform, evaluating care standards and engaging diabetes clinics to refine treatment, advancing community understanding. This data-driven approach yields tangible patient improvements.
Founded in 2009 by Dana Ball and Marie Schiller, T1D Exchange addressed a critical need to accelerate progress and enhance clinical care for the type 1 diabetes community. Initial Helmsley Charitable Trust funding enabled them to build a robust, data-driven ecosystem tackling complex challenges of living with the condition.
T1D Exchange serves individuals with type 1 diabetes, clinical researchers, and healthcare providers. It integrates patient perspectives and data to inform research priorities, optimizing care delivery. The organization envisions a future where people with type 1 diabetes achieve better health outcomes and a higher quality of life via continuous treatment advancements and comprehensive support.
T1D Exchange has 1 tracked investment across 1 company. The latest tracked deal is $18.0M Series B in Bigfoot Biomedical in March 2018.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2018 | Bigfoot Biomedical | $18.0M Series B | — | Eclipse Ventures, Abbott, Cormorant Asset Management, Janus Henderson Investors, JDRF T1D Fund, Quadrant Capital Advisors, Senvest Management, Visionnaire Ventures |
